The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Sequencing CAR T-cell therapy and bispecifics after BCMA-directed treatment in mutliple myeloma
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, discusses sequencing strategies for CAR T-cell therapies and bispecific antibodies in relapsed/refractory multiple myeloma. He highlights the potential benefit of switching targets after BCMA-directed CAR T-cell therapy and reviews the activity of talquetamab-based approaches in patients who relapse following BCMA-targeted treatment.This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There is some data on the use of bispecific antibodies after receipt of CAR T-cell therapy. Now, the caveat here is that that data has been generated in patients who’ve relapsed many times over. But what we see is that if you change target, that seems to be a preferred pathway. In other words, if you get a BCMA target CAR T-cell therapy, the BCMA bispecific antibody subsequently doesn’t perform so well...
There is some data on the use of bispecific antibodies after receipt of CAR T-cell therapy. Now, the caveat here is that that data has been generated in patients who’ve relapsed many times over. But what we see is that if you change target, that seems to be a preferred pathway. In other words, if you get a BCMA target CAR T-cell therapy, the BCMA bispecific antibody subsequently doesn’t perform so well. That said, talquetamab performs quite well after relapse from BCMA CAR T-cell therapy with a median progression-free survival of 13 months in heavily pretreated patients, which is just as good as those patients who have not gotten CAR T-cell therapy. So another nice space for, say, for example, talquetamab and daratumumab would be a patient who’s relapsing after a BCMA targeted CAR T-cell therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
